- Home
- AQST vs MREO Comparison
AQST vs MREO Comparison
Compare AQST & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQST
- MREO
- Stock Information
- Founded
- AQST 2004
- MREO 2015
- Country
- AQST United States
- MREO United Kingdom
- Employees
- AQST N/A
- MREO N/A
- Industry
- AQST Biotechnology: Pharmaceutical Preparations
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- AQST Health Care
- MREO Health Care
- Exchange
- AQST Nasdaq
- MREO Nasdaq
- Market Cap
- AQST 502.6M
- MREO 577.6M
- IPO Year
- AQST 2018
- MREO N/A
- Fundamental
- Price
- AQST $4.41
- MREO $3.53
- Analyst Decision
- AQST Strong Buy
- MREO Strong Buy
- Analyst Count
- AQST 7
- MREO 4
- Target Price
- AQST $9.43
- MREO $7.50
- AVG Volume (30 Days)
- AQST 1.7M
- MREO 690.6K
- Earning Date
- AQST 11-04-2024
- MREO 11-12-2024
- Dividend Yield
- AQST N/A
- MREO N/A
- EPS Growth
- AQST N/A
- MREO N/A
- EPS
- AQST N/A
- MREO N/A
- Revenue
- AQST $58,900,000.00
- MREO $1,000,000.00
- Revenue This Year
- AQST $18.45
- MREO $16.39
- Revenue Next Year
- AQST N/A
- MREO $9.44
- P/E Ratio
- AQST N/A
- MREO N/A
- Revenue Growth
- AQST 22.56
- MREO N/A
- 52 Week Low
- AQST $1.69
- MREO $1.86
- 52 Week High
- AQST $6.23
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- AQST 37.69
- MREO 28.70
- Support Level
- AQST $4.62
- MREO $4.05
- Resistance Level
- AQST $5.59
- MREO $4.40
- Average True Range (ATR)
- AQST 0.37
- MREO 0.19
- MACD
- AQST -0.11
- MREO -0.06
- Stochastic Oscillator
- AQST 2.54
- MREO 2.81
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).